Our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those with cancer begins with a very considered step forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of Purpose™.
Please note, congress material is in parts promotional and is intended for European, Middle Eastern and African healthcare professionals only. Should you wish to proceed please enter login details.
In that time, we have designed, developed and delivered treatments that change what it means to have, and to treat, cancer. We have years of outstanding legacy in haematological malignancies and prostate cancer. In fact, in the last 7 years, we have launched five new oncology treatments in Europe. What's more, we have four more treatments currently under investigation in phase III clinical trials.
We recognise that every cancer is different, each possessing unique challenges along the way. But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference.
Worldwide in 2020 there were an estimated 19.3 million new cancer cases and 9.9 million deaths. Cancer brings devastation. Patients, their families, and the entire oncology community deserve meaningful change. At Janssen Oncology, we consistently integrate their perspectives into everything we do. But we don’t just listen, we use insight to create solutions that make a truly meaningful difference.
To help us achieve this we are privileged to have the support and participation of internationally renowned experts who form our scientific committee and faculties. Their involvement ensures we continue to provide clinically relevant and balanced education.
EGFR, epidermal growth factor receptor. FGFR, fibroblast growth factor receptor. NSCLC, non-small cell lung cancer.
Date of preparation: June 2021 | CP-232494